bitFlyer launches ‘Instant Buy’ to make buying cryptocurrency more accessible
5.12.2019 10:00:00 EET | Business Wire | Press release
Today, leading cryptocurrency exchange bitFlyer has announced the launch of Instant Buy on its Buy/Sell exchange platform in Europe. The feature, available on desktop and smartphone, allows users to buy cryptocurrency directly from bitFlyer, using credit card, debit card or local instant transfer methods such as Sofort, iDeal and GiroPay.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005083/en/
Instant Buy is now available with bitFlyer Buy/Sell (Photo: Business Wire)
Instant Buy is built for users looking for the fastest and simplest way to buy cryptocurrencies, as well as beginners looking for an all-in-one solution for purchasing, storing and securing their cryptocurrency investments.
Andy Bryant, Co-head and COO at bitFlyer Europe, said: “Instant Buy is the latest upgrade to bitFlyer’s Buy/Sell platform, as part of our goal to create a simpler, faster and transparent experience when it comes to buying virtual currencies. By making it similar to that of a traditional e-commerce experience, we are helping bringing cryptocurrency to a mainstream audience, while also giving experienced users a faster and simpler way to get their currency.”
This new feature, following bitFlyer’s recent app launch, is the latest development in a major growth strategy by the European side of the business in line with its vision to break down barriers to entry that many face while investing in cryptocurrency. Whilst the bitFlyer app has made it even easier for users to buy and sell from their smartphones, Instant Buy makes it more convenient for users to buy coins using their preferred payment method.
Other key features of Instant Buy include:
- Built for users looking for the fastest and simplest way to buy cryptocurrencies, as well as new adopters looking for an all-in-one solution to purchase, store and secure their investments
- Allows users to purchase cryptocurrencies (including the less mainstream altcoins such as Lisk, Monacoin and Ethereum Classic) directly from the bitFlyer platform at a predefined price, making the purchase experience significantly more straightforward
- Any fees related to payment processing are clearly displayed. bitFlyer does not charge additional fees on top of those that may be charged by payment service providers
bitFlyer launched in the USA in November 2017, followed by bitFlyer Europe in January 2018, both as fully owned subsidiaries of bitFlyer, Inc., a household name in the cryptocurrency space in Japan and one of the longest-standing cryptocurrency exchanges. It is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined and has also recently been recognised as one of only 10 exchanges that isn’t faking trading volumes.
ENDS
About bitFlyer EUROPE S.A.
bitFlyer EUROPE S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell virtual currencies. bitFlyer EUROPE S.A. site: https://bitflyer.com/en-eu/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005083/en/
Contact information
Lauren Armour
Tyto PR
+44(0)7826 557 326
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom